18-methylsegesterone acetate

18-Methylsegesterone Acetate (also known as 18-MGA) is a progestin medication which is used in contraceptive technology and has been researched for use in female reproductive health. It is a derivative of progesterone, a naturally occurring hormone that plays a crucial role in the menstrual cycle and in maintaining the early stages of pregnancy.

History

18-Methylsegesterone Acetate was first synthesized in the 1960s by the pharmaceutical company Schering AG. It was developed as part of a wider effort to create more effective and reliable contraceptive methods.

Pharmacology

As a progestin, 18-Methylsegesterone Acetate works primarily by preventing ovulation and thickening the cervical mucus, which makes it harder for sperm to reach the uterus. It also changes the lining of the uterus, making it less likely for a fertilized egg to attach and develop into a pregnancy.

Medical Uses

18-Methylsegesterone Acetate is used in contraceptive technology, specifically in contraceptive implants. These implants are small, thin rods that are inserted under the skin of the upper arm. They release a steady dose of the progestin, providing contraception for up to three years.

Research

Research into the use of 18-Methylsegesterone Acetate in female reproductive health is ongoing. Studies have investigated its potential use in treating conditions such as endometriosis and uterine fibroids, as well as its potential as a component of hormone replacement therapy.

See Also

• Progestin
• Contraceptive implant
• Schering AG

References

‎